Patient Selection for Belantamab Mafodotin

This Around the Practice program opens with an overview of belantamab mafodotin, a B-cell maturation antigen (BCMA)-directed antibody-drug conjugate (ADC)approved in October 2025 with bortezomib and dexamethasone for adults with relapsed or refractory multiple myeloma after at least 2 prior lines of therapy, including a proteasome inhibitor and an immunomodulatory agent. The moderator notes the combination’s category 1 National Comprehensive Cancer Network (NCCN) guideline recommendation,every-3-week weight-based infusion, boxed warning for ocular toxicity, and restricted Risk Evaluation and Mitigation Strategy (REMS). One panelist then describes the last patient he saw who had already been through a proteosome inhibitor and immunomodulatory agent and the factors he took into consideration in his treatment decision.